JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stringer, S. E.
Right arrow Articles by Gallagher, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stringer, S. E.
Right arrow Articles by Gallagher, J. T.

J Biol Chem, Vol. 274, Issue 36, 25455-25460, September 3, 1999


Heparin Is a Unique Marker of Progenitors in the Glial Cell Lineage*

Sally E. StringerDagger §, Margot Mayer-Proschel, Anjali Kalyaniparallel , Mahendra Raoparallel , and John T. Gallagher**

From the Cancer Research Campaign, Dagger  Drug Development and Imaging Section, Paterson Institute of Cancer Research and the ** Medical Oncology Department (University of Manchester), Christie Hospital, Wilmslow Road, Manchester M20 4BX, United Kingdom, the  Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, and the parallel  Department of Neurobiology and Anatomy, University of Utah Medical School, Salt Lake City, Utah 84132

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The oligodendrocyte-type-2 astrocyte progenitor cells (precursors of oligodendrocytes and type-2 astrocytes) are an excellent system in which to study differentiation as they can be manipulated in vitro. Maintenance of oligodendrocyte-type-2 astrocyte progenitor cells requires basic fibroblast growth factor, a growth factor whose action normally depends on a heparan sulfate coreceptor. Biochemical analysis revealed a most surprising result: that the oligodendrocyte-type-2 astrocyte progenitors did not synthesize heparan sulfate, the near ubiquitous N-sulfated cell surface polysaccharide, but the chemically related heparin in a form that was almost completely N- and O-sulfated. The heparin was detected in the pericellular fraction of the cells and the culture medium. In contrast the differentiated glial subpopulations (oligodendrocytes and type-2 astrocytes) synthesized typical heparan sulfate but with distinctive fine structural features for each cell type. Thus heparin is a unique differentiation marker in the glial lineage. Previously heparin has been found only in a subset of mature mast cells called the connective tissue mast cells. Its presence within the developing nervous system on a precise population of progenitors may confer specific and essential recognition properties on those cells in relation to binding soluble growth and/or differentiation factors and the extracellular matrix.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the developing rat optic nerve, bipotential glial progenitor cells (O-2A1 progenitors) give rise to both oligodendrocytes, which myelinate central nervous system axons, and type-2 astrocytes, which have been proposed to contact the axons between adjacent myelinated regions at nodes of Ranvier (1). Small numbers of O-2A progenitors are found in the nerve as early as embryonic day 15 (2). They continue to proliferate for several weeks (3, 4) and differentiate in the early postnatal period oligodendrocytes appearing before the type-2 astrocytes (5).

The O-2A progenitors represent one of the few cell types in which most aspects of differentiation and proliferation can be manipulated in a controlled in vitro environment. O-2A progenitors grown in chemically defined medium in the absence of mitogen differentiate rapidly into oligodendrocytes without additional signals (6-8). If, however, they are exposed to appropriate inducing factors like fetal calf serum or bone morphogenic protein-2, the cells differentiate into astrocytes (6, 9-11). Differentiation can be inhibited and O-2A progenitor proliferation maintained by basic fibroblast growth factor (bFGF) used either alone or in combination with PDGFA (12).

It is now well established that many growth factors and cytokines act on target cells via a dual receptor system in which one relatively low affinity receptor facilitates transfer to a higher affinity species essential for cell signaling. In the case of bFGF, and other members of the fibroblast growth factor family, the low affinity receptor is heparan sulfate (HS) (13-15) a near ubiquitous sulfated polysaccharide present on the cell surfaces and in the extracellular matrix as a component of proteoglycans. A number of growth factors such as vascular endothelial growth factor, hepatocyte growth factor, and heparin binding growth-associated molecule (16-18) are also dependent on HSPGs, whereas the effectiveness of others is enhanced by their interaction with HS possibly due to a resultant increase in their pericellular concentration. The long splice variant of PDGFA falls into the latter category (19, 20).

Specific HS species are required to bind to these growth factors (17, 21-24). Permutations in HS structure arise from non-random but variable O-sulfation of saccharides within N-sulfated sections (sulfated domains) of the sugar chain and their immediate flanking sequences. These hypervariable sulfated regions are separated by extended sequences of N-acetylated saccharides of low or zero sulfation (reviewed in Ref. 25). This pattern distinguishes HS from the chemically related heparin, which is essentially highly sulfated along its entire length and in contrast to the ubiquitously distributed HS has so far been found only in a subgroup of mast cells, called the connective tissue mast cells (26).

Studies from a number of groups have shown that the patterns of expression of HSPG core proteins and the structure of HS chains are developmentally regulated and tightly controlled at the cellular level (27, 28). Such changes modify cell responses to extrinsic growth and differentiation factors and may provide guidance cues for axonal pathfinding in the nervous system (29). In the following investigation, the primary O-2A cells were utilized to study changes in HS composition during differentiation of the bipotential progenitor cells into the two functionally and morphologically distinct glial cell lineages. A remarkable switch from heparin expression in the O-2A progenitors to distinctive HS species in the oligodendrocytes and astrocytes was observed.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- PDGFA and bFGF for cell culture were gifts from C. George-Nascimento and L. Coussens (Chiron Corp., Emeryville, CA), recombinant human insulin growth factor-1 a gift from Genentech, ciliary neurotrophic factor from Frank Collins (Synergen) and recombinant human leukemia inhibitory factor from John Heath. Recombinant bFGF used in the affinity experiments was given by David Fernig (Liverpool, United Kingdom (UK)). Poly-L-lysine (Mr 175,000), bovine pancreatic insulin, human transferrin, progesterone, putrescine, L-thyroxine, selenium, soybean trypsin inhibitor, and keratanase (endo-beta -galactosidase, EC 3.2.1.103) were obtained from Sigma (Poole, UK). Bovine serum albumin was from Miles Laboratories Inc.

D-[6-3H]Glucosamine hydrochloride (20-45 Ci/mol) was obtained from NEN Life Science Products (Stevenage, UK). Heparinase I (EC 4.2.2.7) and chondroitinase ABC (EC 4.2.2.4) were from Seikagaku Kogyo Co. (Tokyo, Japan). Heparinase II (no EC number assigned) and heparinase III (EC 4.2.2.8) were obtained from Grampian Enzymes (Orkney Island, UK). Bio-Gel P10 and Affi-Gel 10 were purchased from Bio-Rad (Hemel Hampstead, UK), Sepharose CL-6B and DEAE-Sephacel from Amersham Pharmacia Biotech (St Albans, UK), and ProPac PA1 analytical columns from Dionex (Camberley, Surrey, UK).

Trizol, Superscript II, oligo(dT) primers, and Elongase polymerase were from Life Technologies, Inc. The Advantage PCR pure kit was from CLONTECH (Palo Alto, CA).

Purification of O-2A Progenitor Cells-- O-2A progenitor cells were isolated from the corpus callosum from 7-day-old rats in order to obtain the number of cells for the biochemical assays. The procedure used was as described previously for the isolation of progenitors from the optic nerve (6, 7). Progenitor cells were purified using a specific antibody capture assay adapted to the O-2A lineage, which reproducibly yields cell populations that are 95-100% pure (31). The O-2A progenitor cells were then either maintained as progenitors in the presence of 10 ng/ml bFGF and 10 ng/ml PDGFA (12). Differentiation to oligodendrocytes was achieved by culture in the presence of PDGFA alone (32) and to type-2 astrocytes by addition of 10% fetal calf serum (6). Cell populations that were generated by in vitro differentiation were harvested at a time point where the differentiation process is complete to ensure 99-100% pure homogenous populations (7 days for oligodendrocytes and 4 days for astrocytes). This purity of the cultures was confirmed by staining control dishes with either anti-GalC (a marker for oligodendrocytes) or anti-GFAP, which is expressed on astrocytes.

Radiolabeling and Preparation of Glycosaminoglycans-- HS and other glycosaminoglycans (GAGs) were biosynthetically labeled by incubating the cultures with 10 µCi/ml [3H]glucosamine for 48 h, to enable tracing of the material in the subsequent experiments by scintillation counting. 3H-GAGs were analyzed from the medium, trypsin-released (pericellular), and intracellular fractions. The medium was removed from the cells, and after washing in PBS the cells were treated with 3 ml of 50 µg/ml trypsin in PBS plus 2 mM EGTA per flask for 10 min at 37 °C. Soybean trypsin inhibitor (250 µg/ml) was added, the cell suspension was pelleted in a bench-top centrifuge (1,000 rpm for 10 min), and the supernatant (i.e. pericellular fraction) was removed. The cell pellet was digested with 0.5 mg/ml Pronase in 5 ml of PBS for approximately 16 h at 37 °C, centrifuged for 10 min at 5,000 rpm, and the supernatant (intracellular fraction) taken for analysis.

Each fraction was initially purified by ion-exchange chromatography on a DEAE-Sephacel column (1 cm × 5 cm) equilibrated in PBS. The GAGs were eluted with a gradient of 0.15-1.5 M NaCl in 20 mM sodium phosphate buffer, pH 7.3, at 10 ml/h. Fractions containing radiolabeled GAGs were pooled, desalted by G50 gel filtration chromatography (1 cm × 35 cm column) in 0.1 M NH4HCO3 and lyophilized.

Identification and Digestion of GAGs-- The different GAG types were identified and separated from the heparin/HS using specific degradation enzymes. Briefly HA was detected by treatment with 1 mg/ml bovine testicular hyaluronidase in 0.1 M NaAc, 0.15 M NaCl, pH 5.0, for approximately 16 h at 37 °C. Similarly, CS/DS was identified by their sensitivity to chondroitinase ABC (32) and keratan sulfate by digestion with 1 unit/ml keratanase in 0.2 M NaAc, pH 7.4, for 16 h at 37 °C. The extent of degradation was determined by Sephadex G50 gel filtration chromatography. HS and heparin were detected by their sensitivity to low pH nitrous acid (33).

HS chains were released from proteoglycan core proteins by alkali borohydride treatment and the molecular size distribution determined by CL6B gel chromatography (34).

Enzymatic Degradation of Heparin and HS and Disaccharide Analysis-- Heparinase III enzyme digestion was carried out as described by Stringer and Gallagher (34). Complete depolymerization of the HS chains was carried out by initially digesting with two additions of 20 mIU/ml heparinase I in 0.1 mM calcium acetate, 1 mg/ml bovine serum albumin, pH 7.0, over at least 18 h and subsequently digesting with two additions of 20 mIU/ml amounts of both heparinase II and III. The extent of breakdown was determined by Bio-Gel P10 chromatography.

The disaccharides produced by combined heparinase digestion were repeatedly lyophilized to remove NH4HCO3 and separated by strong anion exchange chromatography on a ProPac column linked to an Anachem HPLC system, equilibrated with double-distilled acidified water, pH 3.0. After sample injection in 2 ml of acidified water, the column was washed with 2 ml of acidified water, followed by elution in a two-step gradient of 0-1 M NaCl, pH 3.0, over 45 ml, then 1-2 M NaCl, pH 3.0, over 3 ml. Disaccharides were identified by comparison with elution positions of eight known standards.

Affinity Chromatography-- To prepare a bFGF affinity gel column, 200 µg of recombinant bFGF was mixed with 200 µg of heparin in 100 µl of coupling buffer (0.1 M HEPES, 80 mM NaCl, pH 7.0) and incubated for 20 min at room temperature. The bFGF was then bound to Affi-Gel 10, and the column prepared as described for a hepatocyte growth factor affinity column by Lyon et al. (17), alongside a control column where the bFGF was omitted.

Affinity experiments were performed by application of radiolabeled HS or CS/DS samples in a 20 mM sodium phosphate buffer containing 0.15 M NaCl and pH 7.3. The sample of HS was recirculated through the column at least five times at room temperature to maximize its opportunity to bind to bFGF. The sample was then eluted by a stepwise NaCl gradient from 0.15 to 2.0 M NaCl in 20 mM sodium phosphate. Fractions (0.5 ml) were collected and monitored for radioactivity.

Detection of Gene Expression by RT-PCR-- Total RNA was isolated from cells or whole tissues by a modification of the guanidine isothiocyanate-phenol-chloroform extraction method using Trizol reagent. cDNA was synthesized from 1-5 µg of total RNA in a 20-µl reaction using Superscript II, a modified Moloney murine leukemia virus reverse transcriptase, and oligo(dT)12-18 primers according to the Life Technologies, Inc. protocol.

Aliquots of cDNA, equivalent to 1/20 of the above reaction, were used in a 50-µl PCR reaction. PCR amplification was performed using Elongase polymerase under conditions recommended by the manufacturer. The 5' and 3' primers, all written 5' to 3', are glypican, GACATACACATTCAGACCC, CTAAGAAACCCACAGACC (product 393 bp); syndecan 1, GACAACTTCTCTGGCTCAGG, CTTCGTCCTTCTTCTTCATCC (735 bp); syndecan 2, GACTATTCTTCTTCTGCCTCTGGC, GGTTTGCGTTCTCCAAGGTC (409 bp); syndecan 3, CCATGCGGTTCATTCCTGAC, CGATGGCATTGTCGTGGAG (800 bp); and syndecan 4, GTCATAGACCCCCAGGACC, CCCTTTTGGGAATGACCTC (267 bp). Reactions were run for 35 cycles. A 10-min incubation at 72 °C added at the end ensured complete extension. The PCR products were purified using the Advantage PCR-Pure kit and their authenticity checked by sequence analysis and restriction enzyme digestion.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteoglycan Expression in O-2A Progenitors and Differentiated Cells-- RNA isolated from primary cultures of O-2A progenitor cells and from cultures allowed to differentiate into oligodendrocytes and astrocytes was analyzed for expression of the most common HSPG types by RT-PCR. Expression of syndecans 1, 2, 3, and 4 and glypican was found in the progenitors, oligodendrocytes, and astrocytes. There was no indication of serglycin expression by RT-PCR using two different sets of mouse primers, as unlike the other proteoglycans mentioned there was no rat serglycin DNA sequence information available. RT-PCR analysis also showed that all of the three cell types expressed the bFGF receptor, FGFR2 type IIIc, with FGFR1 type IIIc additionally expressed by the oligodendrocytes (data not shown).

GAG Composition of the O-2A Progenitors, Oligodendrocytes, and Astrocytes-- Metabolically radiolabeled GAG saccharide chains were isolated and analyzed from primary cultures of O-2A progenitor cells and the differentiated cell types. In all cultures the majority of GAGs were found in the culture medium and CS/DS was consistently the major species (Fig. 1). There was very little intracellular material. HS/heparin, identified on the basis of nitrous acid susceptibility, was present in all cell types with a general tendency for the heparin/HS:CS/DS ratio to increase in the pericellular fraction. There was a dramatic depletion in the level of heparin/HS in the oligodendrocytes compared with the O-2A progenitors with an average decrease of 80% ± 20% in the pericellular fraction, coinciding with a drop in CS/DS levels. In the astrocytes there was always an increase of at least 2-fold in the level of CS in the medium compared with the progenitor cells. Small quantities of HA were present in all of the cultures, and a trace of keratan sulfate was found in the pericellular fraction of the progenitors in one of three preparations of the cells.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 1.   GAG composition of glial progenitors and differentiated cells. 3H-Radiolabeled GAG chains were extracted from the medium (M), pericellular (P), and intracellular (I) fractions of primary O-2A progenitors, and from the oligodendrocytes and astrocytes into which a proportion of them had been differentiated in culture. HA (open bar) was separated from the other GAGs by anion exchange chromatography and its presence confirmed by testicular hyaluronidase digestion. CS/DS (solid bar) were removed from the remaining sulfated GAGs and their levels determined by breakdown with specific enzymes. A tiny amount of keratan sulfate found in the pericellular fraction of one preparation of progenitors was similarly removed by specific enzyme breakdown. The remaining material was confirmed to be HS/heparin (striped bar) by nitrous acid treatment. The histogram depicts mean values from three preparations of cells. The standard errors for each data category are as follows: O-2A progenitors, HA, M 0.003, P 0.008, I 0; HS, M 0.069, P 0.011, I 0; CS, M 0.028, P 0.023, I 0. Oligodendrocytes, HA, M 0.005, P 0.005, I 0.005; HS, M 0.026, P 0.010, I 0; CS, M 0.16, P 0.020, I 0. Astrocytes, HA, M 0.012, P 0.004, I 0.009; HS, M 0.035, P 0.002, I 0; CS, M 0.005, P 0.003, I 0.

Analysis of Heparin/HS Structure-- The heparin/HS was further purified, and the size distribution for each cell type was determined by gel filtration chromatography on Sepharose CL6B (Fig. 2). The peak maxima for the progenitors, oligodendrocytes, and astrocytes corresponded to Kav values of 0.52, 0.49, and 0.42 respectively (Fig. 2) equivalent to mean molecular masses of 20 ± 1.4, 25 ± 3.8, and 31 ± 2.4 kDa by reference to the published calibration of Wasteson (35). No differences were observed in the size range of material isolated from the medium and pericellular fractions for each cell type. The progenitor and oligodendrocyte heparin/HS showed broad size distributions typical of previously isolated HS species, while the astrocyte polysaccharide had a noticeably tighter distribution.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   CL6B-Sepharose gel filtration of HS/heparin chains. The size distribution of the 3H-radiolabeled HS/heparin purified from O-2A progenitor (solid line), oligodendrocyte (dotted line), and astrocyte (dashed line) extracts were compared by CL6B gel filtration chromatography. The position of the column void volume (VO) and total volume (VT) is indicated. The CL6B-Sepharose gel filtration analysis has been carried out several times on the three preparations of the different cell types in Fig. 1.

Heparin/HS from the medium and pericellular compartments was depolymerized by nitrous acid degradation and heparinase III enzyme to compare their structures. The resultant fragments were separated on a Bio-Gel P10 column. In all cases the polysaccharide from the medium and pericellular compartments within each cell type showed essentially the same characteristics.

Treatment with low pH nitrous acid, which cleaves at GlcNSO3 residues, gave striking results for the progenitor polysaccharide, where 94% of the material was broken down to disaccharides, indicating that the material has an N-sulfate content comparable to that of heparin (Fig. 3A). In contrast both the oligodendrocytes and astrocytes showed a typical HS breakdown pattern (Fig. 3, B and C) with a range of different sized nitrous acid-resistant fragments similar to HS extracted from a variety of other cell types (e.g. Ref. 36). Overall the degrees of N-sulfation of the progenitors, oligodendrocytes and astrocytes were 95%, 42%, and 39%, respectively. It was noticeable that the nitrous acid-resistant fragments from the astrocytes HS contained a greater proportion of hexasaccharide and longer fragments than in the oligodendrocyte HS.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Depolymerization of HS/heparin by nitrous acid treatment or heparinase III enzyme digestion. 3H-Radiolabeled heparin/HS from the O-2A progenitors (A and D), oligodendrocytes (B and E), and astrocytes (C and F) were depolymerized by low pH nitrous acid treatment (A-C) or heparinase III enzyme digestion (D-F) and the resultant fragments separated by Bio-Gel P10 gel filtration. The degree of polymerization of the oligosaccharides within each peak and the position of the column void volume (Vo) are indicated. Each of the depolymerization treatments illustrated has been carried out at least three times with heparin/HS from at least two preparations of cells, and the results were consistent.

Heparinase III is proposed to cleave the linkage GlcNAc/GlcNSO3(± 6S)alpha 1,4GlcA/IdoA (36, 37), with a preference for the GlcA-bearing disaccharides. It thereby attacks mainly in the non-sulfated regions releasing N-sulfated fragments enriched in IdoA(2S). The low level of heparinase III cleavage of the progenitor polysaccharide, about 5% susceptible linkages (Fig. 3D), with most of the material eluting in the column void volume (Fig. 3D) indicates an IdoA(2S)-rich, polysaccharide species (i.e. heparin). The switch to HS expression was clearly seen in the two differentiated cell types, the oligodendrocytes and the astrocytes, which had 49% and 54% heparinase III-susceptible linkages, respectively, with a range of different sized sulfated domains being identifiable in the elution profiles (Fig. 3, E and F). Again the profile of the astrocytes was distinct from the oligodendrocytes, with a greater proportion of the longer sulfated domains of decasaccharides and above.

Disaccharide Composition-- Disaccharides were prepared from the three cell types by combined heparinase digestion and separation on Bio-Gel P10, followed by strong anion-exchange HPLC. Analysis of the disaccharide composition (Fig. 4A) confirms the distinctive heparin nature of the progenitor HS, which contained 73% trisulfated disaccharides (UA(2S)-GlcNSO3(6S)) and no N-acetylated disaccharides (Table I). The contrast to the disaccharide elution profiles of the differentiated cell types is immediately apparent (Fig. 4, B and C), where a range of all of the eight disaccharide types commonly seen in HS were present (Table I). In both cases there was over 30% non-sulfated disaccharides and less than 15% were trisulfated. The disaccharide composition of the astrocytes was very similar to that found in human skin fibroblast HS (36). The oligodendrocytes HS disaccharide composition was distinct from the astrocytes, with a significantly higher level of the trisulfated disaccharide.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   Analysis of the disaccharide composition of O-2A progenitor, oligodendrocyte, and astrocyte HS/heparin. Disaccharides that were prepared by exhaustive heparinase enzyme digestion of the [3H]HS/heparin from the O-2A progenitors (A), oligodendrocytes (B), and astrocytes (C) were separated on a ProPac PA1 strong anion exchange HPLC analytical column (4 × 250 mm) eluted with a NaCl gradient as described under "Experimental Procedures." The elution positions of the sample disaccharide peaks, identified by scintillation counting of the eluting fractions, were compared with the elution positions of eight known disaccharide standards as follows: 1, Delta HexA-GlcNAc; 2, Delta HexA-GlcNSO3; 3, Delta HexA-GlcNAc(6S); 4, Delta HexA(2S)-GlcNAc; 5, Delta HexA-GlcNSO3(6S); 6, Delta HexA(2S)-GlcNSO3; 7, Delta HexA(2S)-GlcNAc(6S); 8, Delta HexA(2S)-GlcNSO3(6S), and the sample peaks have been numbered accordingly. The peak depicted by the asterisk is also considered to be standard 1, Delta HexA-GlcNAc, the elution position of which has been found to be extremely sensitive to minute changes in the column environment.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Disaccharide composition of HS from the progenitors and differentiated cells
Disaccharides were prepared by exhaustive heparinase enzymes digestion of the [3H]HS/heparin from the O-2A progenitors, oligodendrocytes (oligos), and astrocytes, resolved by strong anion exchange HPLC as shown in Fig. 4 and quantified.

Affinity of the HS for bFGF-- As bFGF is known to be a key growth factor for regulating the proliferation and differentiation of the O-2A cell type (12), the relative affinities of the different glial HS types for a bFGF Affi-Gel column were compared. In all cases the majority of HS eluted between 0.15 and 1 M NaCl, with a small amount of HS binding at high affinity up to at least 1.6 M NaCl (Fig. 5). A control column did not exhibit any binding of HS above 0.15 M NaCl (data not shown). The progenitor heparin showed stronger binding to the bFGF Affi-Gel than the oligodendrocyte HS with a greater proportion of the material eluting at 0.8 M NaCl and above, while the astrocyte HS elution profile was more analogous to the progenitors. The bFGF affinity of the astrocyte HS was not significantly different from mouse fibroblast HS (Fig. 5B) consistent with their similarity in composition (Fig. 3; Ref. 34). CS/DS from the progenitors and oligodendrocytes showed much weaker binding to the bFGF Affi-Gel, the majority of material eluting between 0.15 M and 0.4 M NaCl with no binding seen above 0.6 M NaCl (data not shown).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   bFGF affinity chromatography of heparin/HS. 3H-Radiolabeled HS/heparin from O-2A progenitors (A, solid block), oligodendrocytes (A, striped block), astrocytes (B, solid block), and mouse 3T3 fibroblasts (B, striped block) were applied to a bFGF Affi-Gel column in 0.15 M NaCl. Bound material was eluted with a stepwise gradient of NaCl, increasing in 0.2 M steps from 0.4 M subsequent to a 0.15 M wash.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The results in this paper clearly indicate that O-2A progenitor cells produce heparin (Figs. 3 and 4). Heparin has only previously been found in connective tissue mast cells. This finding was both interesting and unexpected, and on differentiation to either type-2 astrocytes or oligodendrocytes there was a switch to HS expression. Furthermore neuroepithelial cells, which are thought to be developmental precursors to the O-2A progenitor cells (38-40), produce HS rather than heparin (28).

During heparin/HS biosynthesis (for reviews, see Refs. 25, 41, and 42), the N-deacetylase/N-sulfotransferase (NDST) enzymes commit the polymeric precursor heparan, composed of repeat sequences of GlcAbeta 1-4GlcNAc, to heparin or HS by catalyzing the conversion of an appropriate proportion of GlcNAc residues to GlcNSO3. The simplest explanation of the present results would be that the O-2A progenitors express the NDST isoform isolated from the heparin-synthesizing mouse mastocytoma (NDST2), which catalyzes conversion of over 80% of the GlcNAc residues to GlcNSO3 and the differentiated cells express the rat liver isoform (NDST1) assumed to be important for HS biosynthesis (43). However, these enzymes were found to be widely expressed in murine and human tissues, suggesting that the enzymes work in concert to achieve the level of N-sulfation appropriate to the cell type (43, 44). Overexpression of the mastocytoma enzyme (NDST2) in a human kidney cell line resulted in highly N-sulfated heparin in which the other modifications, e.g. conversion of GlcA to IdoA and polymer O-sulfation were not enhanced (45), demonstrating that the overall structure of the polymer in any individual cell type depends on the coordinated expression of all the modifying enzymes and perhaps also on other regulatory proteins.

In contrast to the connective tissue mast cells, where heparin is stored in intracellular secretory granules attached to the protease-resistant core protein serglycin (46), the O-2A heparin was only found in the medium and pericellular (i.e. trypsin-releasable) fractions (Fig. 1). Furthermore, RT-PCR studies did not detect any expression of the serglycin proteoglycan (data not shown). RT-PCR studies indicated that all four syndecans and glypican HSPGs are expressed in the O-2A progenitors, oligodendrocytes, and astrocytes but it cannot be certain that these O-2A proteoglycans bear the heparin chains.

A novel HSPG that appears to be important in central nervous system development has been found in the primitive neuroepithelial cells (47), which are precursors to the O-2A cells. Analysis of the HS chains from embryonic day 10 (E10) and day 12 (E12) neuroepithelial precursor cells showed that changes in structure in the form of an increase in chain length and 6-O-sulfation in the more committed E12 cells (28) corresponded to a switch in growth factor response of the cells from bFGF in E10 to aFGF in E12. bFGF is also known to be important for the self-renewal property of the O-2A progenitors (12). In this paper we found that the switch from heparin in the O-2A progenitors to the much lower sulfated HS in the oligodendrocytes corresponded to a significant decrease in the apparent bFGF affinity of the polysaccharide chains (Fig. 5). This might be expected, as both N-sulfation and 2-O-sulfation of the HS chains have been found to be important for bFGF binding (21-23), while 6-O-sulfation appears to be critical for biological activation (48-50). However, the astrocyte HS bound bFGF as efficiently as the more highly sulfated progenitor heparin (Fig. 5), possibly as a result of the prevalence of long sulfated domains (dodecasaccharides and larger) within the astrocyte HS (Fig. 3F).

Although oligodendrocytes are postmitotic (51), they still respond to bFGF by down-regulation of myelin-specific markers, re-entrance into the cell cycle without mitosis, and increase in the length of cellular processes (52). The present results indicate that this response to bFGF may be less reliant on the HS coreceptor, which is at low levels (Fig. 1) and has low bFGF affinity (Fig. 5) than other cell systems (13-15) and could possibly be mediated by the signaling receptor FGFR2 type IIIc, which is not found in the the progenitors or astrocytes.

The long splice variant of the other key growth factor in this system, PDGFA (12), has recently been discovered to bind to highly sulfated heparin like oligosaccharides, enriched in the trisulfated disaccharides (24), which form 74% of the O-2A progenitor heparin (Table I). PDGFA is critical for the timing of the O-2A progenitor differentation into oligodendrocytes and astrocytes (31, 51), and heparin may be essential in regulating the PDGFA response.

The specific temporal expression of heparin, in the O-2A progenitors, during central nervous system development suggests that heparin must have a function critical to this lineage or to the adjacent neurons. It would be interesting to discover whether heparin is also produced by the subset of glioblastoma multiforme tumors believed to be derived from the small population of adult O-2A progenitor cells (53), as it might enhance the activity of the myriad of autocrine growth factors mitogenic to glioblastomas (e.g. Refs. 54-57). Similarly, during injury of the central nervous system where reactive astrocytes are thought to revert to a more primitive state (for reviews, see Refs. 58 and 59), reappearance of heparin expression could possibly aid their rapid response. Further study of the heparin produced by O-2A progenitors could give important insights into the control of heparin and HS biosynthesis and their role in both development and disease states.

    ACKNOWLEDGEMENTS

We gratefully acknowledge Naomi Chadderton and Abdul Patel (Paterson Institute of Cancer Research, Manchester, UK), and Samuel Bernard (University of Utah, Salt Lake City, UT) for technical assistance. We also acknowledge Mark Noble (University of Utah, Salt Lake City, UT) for advice and support.

    FOOTNOTES

* This work was supported by the Cancer Research Campaign and the Huntsman Cancer Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom all correspondence should be addressed. Tel.: 44-161-446-3035; Fax: 44-161-446-3109; E-mail: sstringer@picr.man.ac.uk.

    ABBREVIATIONS

The abbreviations used are: O-2A, oligodendrocyte-type-2 astrocyte; 2S, 2-OSO3; 6S, 6-OSO3; bFGF, basic fibroblast growth factor; bp, base pair(s); CS, chondroitin sulfate; DS, dermatan sulfate; E, embryonic day; FGFR, fibroblast growth factor receptor; GlcA, beta -D-glucuronate; GlcNAc, alpha -D-N-acetylglucosamine; GlcNSO3, alpha -D-N-sulfoglucosamine; GAG, glycosaminoglycan; HA, hyaluronic acid; HPLC, high performance liquid chromatography; HS, heparan sulfate; HSPG, HS proteoglycan; IdoA, alpha -L-iduronate; NDST, N-deacetylase/N-sulfotransferase; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PDGFA, platelet-derived growth factor A; RT-PCR, reverse transcription-polymerase chain reaction; Delta HexA, Delta 4,5-unsaturated hexuronate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. ffrench-Constant, C., and Raff, M. C. (1986) Nature 323, 335-338[CrossRef][Medline] [Order article via Infotrieve]
2. Small, R. K., Riddle, P., and Noble, M. (1987) Nature 328, 155-157[CrossRef][Medline] [Order article via Infotrieve]
3. Skoff, R. P., Price, D. L., and Stocks, A. (1976) J. Comp. Anat. 169, 291-311
4. Skoff, R. P., Price, D. L., and Stocks, A. (1976) J. Comp. Anat. 169, 313-323
5. Miller, R. H., David, S., Patel, R., Abney, E. R., and Raff, M. C. (1985) Dev. Biol. 111, 35-41[CrossRef][Medline] [Order article via Infotrieve]
6. Raff, M. C., Miller, R. H., and Noble, M. (1983) Nature 303, 390-396[CrossRef][Medline] [Order article via Infotrieve]
7. Noble, M., and Murray, K. (1984) EMBO J. 3, 2243-2247[Medline] [Order article via Infotrieve]
8. Raff, M. C., Abney, E. R., and Fok-Seang, J. (1985) Cell 42, 61-69[CrossRef][Medline] [Order article via Infotrieve]
9. Hughes, S. M., Lillien, L. E., Raff, M. C., Rohrer, H., and Sendtner, M. (1988) Nature 335, 70-73[CrossRef][Medline] [Order article via Infotrieve]
10. Lillien, L. E., Sendtner, M., Rohrer, H., Hughes, S. M., and Raff, M. C. (1988) Neuron 1, 485-494[CrossRef][Medline] [Order article via Infotrieve]
11. Mabie, P. C., Mehler, M. F., Marmur, R., Papavasiliou, A., Song, Q., and Kessler, J. A. (1997) J. Neurosci. 17, 4112-4120[Abstract/Free Full Text]
12. Bogler, O., Wren, D., Barnett, S. C., Land, H., and Noble, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6368-6372[Abstract/Free Full Text]
13. Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., and Ornitz, D. M. (1991) Cell 64, 841-848[CrossRef][Medline] [Order article via Infotrieve]
14. Rapraeger, A. C., Krufta, A., and Olwin, B. B. (1991) Science 252, 1705-1708[Abstract/Free Full Text]
15. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E., and Leder, P. (1992) Mol. Cell. Biol. 12, 240-247[Abstract/Free Full Text]
16. Gitay-Goren, H., Soker, S., Vlodavsky, I., and Neufeld, G. (1992) J. Biol. Chem. 267, 6093-6098[Abstract/Free Full Text]
17. Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T., and Gallagher, J. T. (1994) J. Biol. Chem. 269, 11216-11223[Abstract/Free Full Text]
18. Kinnunen, T., Raulo, E., Nolo, R., Maccarana, M., Lindahl, U., and Rauvala, H. (1996) J. Biol. Chem. 271, 2243-2248[Abstract/Free Full Text]
19. Kelly, J. L., Sanchez, A., Brown, G. S., Chesterman, C. N., and Sleigh, M. J. (1993) J. Cell Biol. 121, 1153-1163[Abstract/Free Full Text]
20. Andersson, M., Ostman, A., Westermark, B., and Heldin, C.-H. (1994) J. Biol. Chem. 269, 926-930[Abstract/Free Full Text]
21. Turnbull, J. E., Fernig, D. G., Ke, Y., Wilkinson, M., and Gallagher, J. T. (1992) J. Biol. Chem. 267, 10337-10341[Abstract/Free Full Text]
22. Habuchi, H., Suzuki, S., Saito, T., Tamura, T., Harada, T., Yoshida, K., and Kimata, K. (1992) Biochem. J. 285, 805-813
23. Maccarana, M., Casu, B., and Lindahl, U. (1993) J. Biol. Chem. 268, 23898-23905[Abstract/Free Full Text]
24. Feyzi, E., Lustig, F., Fager, G., Spillmann, D., Lindahl, U., and Salmivirta, M. (1997) J. Biol. Chem. 272, 5518-5524[Abstract/Free Full Text]
25. Stringer, S. E., and Gallagher, J. T. (1997) Int. J. Biochem. Cell Biol. 29, 709-714[CrossRef][Medline] [Order article via Infotrieve]
26. Linhart, R. J., Ampofo, S. A., Fareed, J., Hoppensteadt, D., Mulliken, J. B., and Folkman, J. (1992) Biochemistry 31, 12441-12445[CrossRef][Medline] [Order article via Infotrieve]
27. David, G., Bai, X. M., Van Der Schueren, B., Cassiman, J.-J., and Van Der Berghe, H. (1992) J. Cell Biol. 119, 961-975[Abstract/Free Full Text]
28. Brickman, Y. G., Ford, M. D., Gallagher, J. T., Nurcombe, V., Bartlett, P. F., and Turnbull, J. E. (1998) J. Biol. Chem. 273, 4350-4359[Abstract/Free Full Text]
29. Walz, A., McFarlane, S., Brickman, Y. G., Nurcombe, V., Bartlett, P. F., and Holt, C. E. (1997) Development 124, 2421-2430[Abstract]
30. Deleted in proof
31. Raff, M. C., Lillien, L. E., Richardson, W. D., Burne, J. F., and Noble, M. (1988) Nature 333, 562-565[CrossRef][Medline] [Order article via Infotrieve]
32. Turnbull, J. E., and Gallagher, J. T. (1990) Biochem. J. 265, 715-724[Medline] [Order article via Infotrieve]
33. Shively, J. E., and Conrad, H. E. (1976) Biochemistry 15, 3943-3950[CrossRef][Medline] [Order article via Infotrieve]
34. Stringer, S. E., and Gallagher, J. T. (1997) J. Biol. Chem. 272, 20508-20514[Abstract/Free Full Text]
35. Wasteson, A. (1971) J. Chromatogr. 59, 87-97[CrossRef][Medline] [Order article via Infotrieve]
36. Desai, U. R., Wang, H.-M., and Linhardt, R. J. (1993) Biochemistry 32, 8140-8145[CrossRef][Medline] [Order article via Infotrieve]
37. Yamada, S., Murakami, T., Tsuda, H., Yoshida, K., and Sugahara, K. (1995) J. Biol. Chem. 270, 8696-8705
38. Rao, M. S., and Mayer-Proschel, M. (1997) Dev. Biol. 188, 48-63[CrossRef][Medline] [Order article via Infotrieve]
39. Mayer-Proschel, M., Kalyani, A., Mujitaba, T., and Rao, M. S. (1997) Neuron 19, 773-785[CrossRef][Medline] [Order article via Infotrieve]
40. Kalyani, A., Hobson, K., and Rao, M. S. (1997) Dev. Biol. 186, 202-223[CrossRef][Medline] [Order article via Infotrieve]
41. Lindahl, U. (1989) in Heparin: Chemical and Biological Properties, Clinical Applications (Lane, D. A. , and Lindahl, U., eds) , pp. 159-189, Edward Arnold, London
42. Lindahl, U., Lidholt, K., Spillmann, D., and Kjellen, L. (1994) Thrombosis Res. 75, 1-32[CrossRef][Medline] [Order article via Infotrieve]
43. Kusche-Gullberg, M., Eriksson, I., Pikas, D. S., and Kjellen, L. (1998) J. Biol. Chem. 273, 11902-11907[Abstract/Free Full Text]
44. Aikawa, J., and Esko, J. D. (1999) J. Biol. Chem. 274, 2690-2695[Abstract/Free Full Text]
45. Cheung, W.-F., Eriksson, I., Kusche-Gullberg, M., Lindahl, U., and Kjellen, L. (1996) Biochemistry 35, 5250-5256[CrossRef][Medline] [Order article via Infotrieve]
46. Stevens, R. L., Avraham, S., Gartner, M. C., Bruns, G. A. P., Austen, K. F., and Weis, J. H. (1988) J. Biol. Chem. 263, 7287-7291[Abstract/Free Full Text]
47. Joseph, S. J., Ford, M. D., Barth, C., Portbury, S., Bartlett, P. F., Nurcombe, V., and Greferath, U. (1996) Development 122, 3443-3452[Abstract]
48. Rusnati, M., Coltrini, D., Caccia, P., Dell'Era, P., Zoppetti, G., Oreste, P., Vasaina, B., and Presta, M. (1994) Biochem. Biophys. Res. Commun. 203, 450-458[CrossRef][Medline] [Order article via Infotrieve]
49. Guimond, S., Maccarana, M., Olwin, B. B., Lindahl, U., and Rapraeger, A. C. (1993) J. Biol. Chem. 268, 23906-23914[Abstract/Free Full Text]
50. Pye, D. A., Vives, R. R., Turnbull, J. E., Hyde, P., and Gallagher, J. T. (1998) J. Biol. Chem. 273, 22936-22942[Abstract/Free Full Text]
51. Lillien, L. E., and Raff, M. C. (1990) Neuron 5, 111-119[CrossRef][Medline] [Order article via Infotrieve]
52. Bansal, R., and Pfeiffer, S. E. (1997) J. Neurosci. Res. 50, 215-228[CrossRef][Medline] [Order article via Infotrieve]
53. Noble, M., and Mayer-Proschel, M. (1997) J. Neuro-Oncol. 35, 193-209[CrossRef][Medline] [Order article via Infotrieve]
54. Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., and Schlessinger, J. (1985) Nature 313, 144-147[CrossRef][Medline] [Order article via Infotrieve]
55. Maxwell, M., Naber, S. P., Wolfe, H. J., Hedley-Whyte, E. T., Galanopoulos, T., Neville-Golden, J., and Antoniades, H. N. (1991) Cancer Res. 51, 1345-1351[Abstract/Free Full Text]
56. Hamel, W., Westphal, M., and Shepard, H. M. (1992) Int. J. Oncol. 1, 673-682
57. Vassbotn, F. S., Ostman, A., Langeland, N., Holmsen, H., Westermark, B., Heldin, C.-H., and Nister, M. (1994) J. Cell. Physiol. 158, 381-389[CrossRef][Medline] [Order article via Infotrieve]
58. Norenberg, M. D. (1996) in The Role of Glia in Neurotoxicity (Aschner, M. , and Kimelberg, H. K. K., eds) , pp. 93-107, CRC Press, Boca Raton, FL
59. Aschner, M. (1998) NeuroToxicol. 19, 269-282 [Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
DevelopmentHome page
K. Grobe, M. Inatani, S. R. Pallerla, J. Castagnola, Y. Yamaguchi, and J. D. Esko
Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function
Development, August 15, 2005; 132(16): 3777 - 3786.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. K. Lau, C. D. Paavola, Z. Johnson, J.-P. Gaudry, E. Geretti, F. Borlat, A. J. Kungl, A. E. Proudfoot, and T. M. Handel
Identification of the Glycosaminoglycan Binding Site of the CC Chemokine, MCP-1: IMPLICATIONS FOR STRUCTURE AND FUNCTION IN VIVO
J. Biol. Chem., May 21, 2004; 279(21): 22294 - 22305.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
A. K. Powell, E. A. Yates, D. G. Fernig, and J. E. Turnbull
Interactions of heparin/heparan sulfate with proteins: Appraisal of structural factors and experimental approaches
Glycobiology, April 1, 2004; 14(4): 17R - 30R.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
S. E. Stringer, B. S. Kandola, D. A. Pye, and J. T. Gallagher
Heparin sequencing
Glycobiology, February 1, 2003; 13(2): 97 - 107.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B.-M. Loo and M. Salmivirta
Heparin/Heparan Sulfate Domains in Binding and Signaling of Fibroblast Growth Factor 8b
J. Biol. Chem., August 30, 2002; 277(36): 32616 - 32623.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. K. Powell, D. G. Fernig, and J. E. Turnbull
Fibroblast Growth Factor Receptors 1 and 2 Interact Differently with Heparin/Heparan Sulfate. IMPLICATIONS FOR DYNAMIC ASSEMBLY OF A TERNARY SIGNALING COMPLEX
J. Biol. Chem., August 2, 2002; 277(32): 28554 - 28563.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
K Prydz and K. Dalen
Synthesis and sorting of proteoglycans
J. Cell Sci., January 1, 2000; 113(2): 193 - 205.
[Abstract] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stringer, S. E.
Right arrow Articles by Gallagher, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stringer, S. E.
Right arrow Articles by Gallagher, J. T.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH